Search PubMed⌕ Search

Biomedical subjects

S Goldstein

Publications and source records attributed to S Goldstein.

758 records · Page 43Linked to original sources

Establishing a protocol to quantify leaflet fibroblast responses to physiologic flow through a viable heart valve.

Mechanical stresses are thought to affect the metabolism of a variety of cell types. Little quantitative data exist regarding heart valve leaflet fibroblast activity after dynamic loading. The goal of this study was to examine leaflet fibroblast function and differentiation in response to flow through an intact valve. This requires the development of a flow system capable of reproducing the valve's native environment, as well as assay protocols to analyze cellular viability and protein and collagen synthesis. As a tool to expose viable tissue valves to physiologic flow, a sterilizable pulsatile flow system has been developed to recreate the dynamic flow environment of the aortic valve while preventing contamination from room air. Physiologic flow conditions [frequency 70 bpm, aortic pressure 129/82 mmHg (systolic/diastolic), cardiac output 2.3 L/min] were sustained for 71 hr without microbiologic contamination. Analytic tools for assessment of fibroblast function include a viability assay, which demonstrated that leaflet viability decreases after prolonged exposure to antibiotics. Proline incorporation studies revealed that 11 times more protein is retained by leaflet tissue than is released into the medium, and 27% of this protein is collagen. Polyacrylamide gel electrophoresis clearly resolved collagen Types I and III from both prepared standards as well as leaflet extracts. In ongoing work, the sterile flow loop will be used to expose fresh porcine aortic valves to defined flow conditions, and the viability and protein/collagen biosynthetic activity of leaflet fibroblasts in response to flow will be quantified. These experiments will provide a baseline by which to design and evaluate future tissue engineered substitutes.

Animals↗

Substituting clozapine for olanzapine in psychiatrically stable Parkinson's disease patients: results of an open label pilot study.

Psychosis induced by the standard drugs for treating idiopathic Parkinson's disease (PD) occurs, in the long term, in approximately 5-8% of patients. Until the development of atypical antipsychotic drugs, treatment of this psychosis was extremely limited and unsatisfactory. Clozapine has been reported to be an effective and well-tolerated treatment for this problem. Clozapine, however, is a difficult drug to use as a result of the monitoring system mandated by the Food and Drug Administration because of the potential for agranulocytosis. Treatment with risperidone has been shown to be poorly-tolerated. This article reports on the authors' open label experience with the newest atypical antipsychotic, olanzapine, and the switching of stable patients from clozapine to olanzapine. Nine of twelve subjects were unable to make the transition because of worsened parkinsonism. Most subjects preferred taking clozapine, despite the onerous monitoring procedure.

Aged↗